Literature DB >> 15030973

Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat.

Gerald U Denk1, Carol J Soroka, Yasuaki Takeyama, Wen-Sheng Chen, John D Schuetz, James L Boyer.   

Abstract

BACKGROUND/AIMS: Multidrug resistance-associated protein 4 (Mrp4, ABCC4) transports cyclic nucleotides, anti-retroviral compounds, and sulfated bile acids. Mrp4 expression is increased in farnesyl/bile acid receptor knockout mice. Our aim was to investigate Mrp4 expression and function in rat liver and kidney in obstructive cholestasis.
METHODS: Male Sprague-Dawley rats were subjected to bile duct ligation (BDL) or sham-surgery. Animals were sacrificed after 3, 7, and 14 days and tissues were harvested for Western blot analysis, real-time reverse transcriptase-mediated polymerase chain reaction (RT-PCR), and immunohistochemistry.
RESULTS: Western blot analysis revealed a progressive, more than seven-fold increase (P < 0.05) of Mrp4 expression in cholestatic livers, 14 days after BDL. In contrast, Mrp4 in 14-day BDL kidneys decreased to 26+/-4% of controls (P < 0.005). Immunohistochemistry localized Mrp4 to the basolateral hepatocyte membrane and corroborated its hepatic up-regulation after BDL. Real-time RT-PCR demonstrated no major changes of Mrp4 mRNA levels in liver and kidney after BDL. Cyclic adenosine monophosphate, an MRP4 substrate, was increased in plasma and urine, consistent with these findings.
CONCLUSIONS: Obstructive cholestasis in rats results in progressive up-regulation of Mrp4 protein in liver but down-regulation in kidney. The absence of corresponding changes in Mrp4 mRNA suggests posttranscriptional mechanisms as predominant regulators of Mrp4 expression in BDL rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030973     DOI: 10.1016/j.jhep.2003.12.001

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  43 in total

Review 1.  Getting the mOST from OST: Role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism.

Authors:  Paul A Dawson; Melissa L Hubbert; Anuradha Rao
Journal:  Biochim Biophys Acta       Date:  2010-06-09

2.  Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance.

Authors:  François R Jornayvaz; Hui-Young Lee; Michael J Jurczak; Tiago C Alves; Fitsum Guebre-Egziabher; Blas A Guigni; Dongyan Zhang; Varman T Samuel; J Enrique Silva; Gerald I Shulman
Journal:  Endocrinology       Date:  2011-12-06       Impact factor: 4.736

3.  Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes.

Authors:  Nathan D Pfeifer; Kyunghee Yang; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2013-09-10       Impact factor: 4.030

4.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

5.  Renal elimination of organic anions in cholestasis.

Authors:  Adriana Monica Torres
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

6.  MCD diet-induced steatohepatitis is associated with alterations in asymmetric dimethylarginine (ADMA) and its transporters.

Authors:  Laura G Di Pasqua; Clarissa Berardo; Vittoria Rizzo; Plinio Richelmi; Anna Cleta Croce; Mariapia Vairetti; Andrea Ferrigno
Journal:  Mol Cell Biochem       Date:  2016-06-29       Impact factor: 3.396

7.  Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.

Authors:  Katharina Brandl; Phillipp Hartmann; Lily J Jih; Donald P Pizzo; Josepmaria Argemi; Meritxell Ventura-Cots; Sally Coulter; Christopher Liddle; Lei Ling; Stephen J Rossi; Alex M DePaoli; Rohit Loomba; Wajahat Z Mehal; Derrick E Fouts; Michael R Lucey; Francisco Bosques-Padilla; Philippe Mathurin; Alexander Louvet; Guadalupe Garcia-Tsao; Elizabeth C Verna; Juan G Abraldes; Robert S Brown; Victor Vargas; Jose Altamirano; Juan Caballería; Debbie Shawcross; Peter Stärkel; Samuel B Ho; Ramon Bataller; Bernd Schnabl
Journal:  J Hepatol       Date:  2018-04-12       Impact factor: 25.083

Review 8.  Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Authors:  Gustav Paumgartner
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 9.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

10.  IGF-1R contributes to stress-induced hepatocellular damage in experimental cholestasis.

Authors:  Axelle Cadoret; Colette Rey; Dominique Wendum; Khaldoun Elriz; François Tronche; Martin Holzenberger; Chantal Housset
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.